<DOC>
	<DOC>NCT00816829</DOC>
	<brief_summary>Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.</brief_summary>
	<brief_title>Effect of Fenofibrate on Sleep Apnea Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Having previous diagnosis of sleep apnea not treated with Continuous Positive Airway Pressure (CPAP) or presenting clinical symptoms of sleep apnea Overweight or obese, with BMI &gt;= 25 kg/m² and &lt; 40 kg/m². Known moderate hypertriglyceridemia, with fasting Triglycerides level &gt;= 2.0 and &lt; 6.0 mmol/L within 3 months before the inclusion. indication for immediate CPAP other known endocrine disease, except treated and adequately controlled hypothyroidism renal failure or plasma creatinine level &gt;130 µmol/L current chronic liver disease or ALanine Amino Transferase (ALT)&gt; 2 times the upper normal limit (UNL) symptomatic gallbladder disease known muscular disease or creatine phosphokinase (CK) &gt; 3 times UNL.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>Sleep Apnea Syndromes</keyword>
	<keyword>Fenofibrate</keyword>
	<keyword>Obese</keyword>
	<keyword>Overweight or obese patients</keyword>
</DOC>